Placental protein-13 and pregnancy-associated plasma protein-a as first trimester screening markers for hypertensive disorders and small for gestational age outcomes

Hypertension in Pregnancy

Volumn 30, Issue 4, 2011, Pages 384-395

  Stamatopoulou, Anastasia ^a   Cowans, Nicholas J ^a   Matwejew, Elisabet ^b   Von Kaisenberg, Constantine ^b,c   Spencer, Kevin ^a  

^a KING GEORGE HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Adverse outcome; First trimester; HELLP; Preeclampsia; Screening; SGA

Indexed keywords

BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN BETA SUBUNIT; DISINTEGRIN; PLACENTA PROTEIN; PLACENTA PROTEIN 13; PLACENTAL GROWTH FACTOR; PREGNANCY ASSOCIATED PLASMA PROTEIN A; UNCLASSIFIED DRUG;

ADULT; ADVERSE OUTCOME; ARTICLE; BIRTH WEIGHT; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; CASE CONTROL STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HELLP SYNDROME; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MATERNAL BLOOD; MATERNAL HYPERTENSION; MATERNAL SMOKING; PREECLAMPSIA; PREGNANCY OUTCOME; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEINURIA; SCREENING; SMALL FOR DATE INFANT;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; FETAL GROWTH RETARDATION; GALECTINS; GESTATIONAL AGE; HUMANS; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS;

EID: 80053537981     PISSN: 10641955     EISSN: 15256065     Source Type: Journal    
DOI: 10.3109/10641955.2010.484081     Document Type: Article

References (38)

1. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet 2001; 357:53-56. (Pubitemid 32056505)
2. Mihu D, Costin N, Mihu CM, Seicean A, Ciortea R. HELLP syndrome-a multisystemic disorder. J Gastrointestin Liver Dis 2007; 16:419-424.
3. Sibai BM, Ramadan MK. Acute renal failure in pregnancies complicated by hemolysis, elevated liver enzymes, and low platelets. Am J Obstet Gynecol 1993; 168:1682-1687.
4. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing preeclampsia and its complications. Cochrane Database Syst Rev 2007; CD004659.
5. Hayman R. Hypertension in pregnancy. Curr Obstet Gynaecol 2004; 14:1-10. (Pubitemid 38620285)
6. Walker JJ. Pre-eclampsia. Lancet 2000; 356:1260-1265.
7. Papageorghiou AT, Yu CK, Nicolaides KH. The role of uterine artery Doppler in predicting adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 2004; 18:383-396. (Pubitemid 38950046)
8. Spencer K, Yu CK, Cowans NJ, Otigbah C, Nicolaides KH. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat Diagn 2005; 25:949-953. (Pubitemid 41494994)
9. Lawrence JB, Oxvig C, Overgaard MT, et al. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci USA 1999; 96:3149-3153. (Pubitemid 29148859)
10. Canini S, Prefumo F, Pastorino D, et al. Association between birth weight and first-trimester free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. Fertil Steril 2008; 89:174-178.
11. Cowans NJ, Spencer K. First-trimester ADAM12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system. Prenat Diagn 2007; 27:264-271. (Pubitemid 46450586)
12. Spencer CA, Allen VM, Flowerdew G, Dooley K, Dodds L. Low levels of maternal serum PAPP-A in early pregnancy and the risk of adverse outcomes. Prenat Diagn 2008; 28:1029-1036. (Pubitemid 352789469)
13. Pilalis A, Souka AP, Antsaklis P, et al. Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler and PAPP-A at 11-14 weeks gestation. Ultrasound Obstet Gynecol 2007; 29:135-140. (Pubitemid 46326584)
14. Poon LC, Maiz N, Valencia C, Plasencia W, Nicolaides KH. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol 2009; 33:23-33.
15. Spencer K, Cowans NJ, Nicolaides KH. Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia. Prenat Diagn 2008; 28:7-10. (Pubitemid 351251982)
16. Than NG, Pick E, Bellyei S, et al. Functional analyses of placental protein 13/galectin-13. Eur J Biochem 2004; 271:1065-1078. (Pubitemid 38373040)
17. Burger O, Pick E, Zwickel J, et al. Placental protein 13 (PP-13): Effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies. Placenta 2004; 25:608-622. (Pubitemid 38950314)
18. Sekizawa A, Purwosunu Y, Yoshimura S, et al. PP13 mRNA expression in trophoblasts from preeclamptic placentas. Reprod Sci 2009; 16:408-413.
19. Shimizu H, Sekizawa A, Purwosunu Y, et al. PP13 mRNA expression in the cellular component of maternal blood as a marker for preeclampsia. Prenat Diagn 2009; 29(13):1231-1236.
20. Than NG, Abdul RO, Magenheim R, et al. Placental protein 13 (galectin-13) has decreased placental expression but increased shedding and maternal serum concentrations in patients presenting with preterm pre-eclampsia and HELLP syndrome. Virchows Arch 2008; 453:387-400.
21. Akolekar R, Syngelaki A, Beta J, Kocylowski R, Nicolaides KH. Maternal serum placental protein 13 at 11-13 weeks of gestation in preeclampsia. Prenat Diagn 2009; 29(12): 1103-1108.
22. Chafetz I, Kuhnreich I, Sammar M, et al. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol 2007; 197:35-37.
23. Gonen R, Shahar R, Grimpel YI, et al. Placental protein 13 as an early marker for preeclampsia: A prospective longitudinal study. BJOG 2008; 115:1465-1472.
24. Huppertz B, Sammar M, Chefetz I, Neumaier-Wagner P, Bartz C, Meiri H. Longitudinal determination of serum placental protein 13 during development of preeclampsia. Fetal Diagn Ther 2008; 24:230-236.
25. Khalil A, Cowans NJ, Spencer K, Goichman S, Meiri H, Harrington K. First trimester maternal serum placental protein 13 for the prediction of pre-eclampsia in women with a priori high risk. Prenat Diagn 2009; 29(8):781-789.
26. Nicolaides KH, Bindra R, Turan OM, et al. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol 2006; 27:13-17. (Pubitemid 43129084)
27. Romero R, Kusanovic JP, Than NG, et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol 2008; 199:122.
28. Spencer K, Cowans NJ, Chefetz I, Tal J, Meiri H. First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of preeclampsia. Ultrasound Obstet Gynecol 2007; 29:128-134. (Pubitemid 46326583)
29. Spencer K, Cowans NJ, Chefetz I, Tal J, Kuhnreich I, Meiri H. Second-trimester uterine artery Doppler pulsatility index and maternal serum PP13 as markers of pre-eclampsia. Prenat Diagn 2007; 27:258-263. (Pubitemid 46450585)
30. Cowans NJ, Spencer K, Meiri H. First-trimester maternal placental protein 13 levels in pregnancies resulting in adverse outcomes. Prenat Diagn 2008; 28:121-125. (Pubitemid 351311153)
31. Matwejew E, Cowans NJ, Stamatopoulou A, von Kaisenberg C, Spencer K. Maternal serum ADAM12 as a potential marker for different adverse pregnancy outcomes. Fetal Diagn Ther 2010; 27:32-39.
32. Cowans NJ, Stamatopoulou A, Matwejew E, von Kaisenberg C, Spencer K. First trimester placental growth factor (PlGF) as a marker for hypertensive disorders and SGA. Prenat Diagn 2010; 30:565-570.
33. Davey DA, MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol 1988; 158:892-898.
34. Marsal K, Persson PH, Larsen T, Lilja H, Selbing A, Sultan B. Intrauterine growth curves based on ultrasonically estimated foetal weights. Acta Paediatr 1996; 85:843-848. (Pubitemid 26267023)
35. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 1999; 13:231-237. (Pubitemid 29248329)
36. Spencer K, Bindra R, Nicolaides KH. Maternal weight correction of maternal serum PAPP-A and free beta-hCG MoM when screening for trisomy 21 in the first trimester of pregnancy. Prenat Diagn 2003; 23:851-855. (Pubitemid 37279873)
37. Kang JH, Farina A, Park JH, et al. Down syndrome biochemical markers and screening for preeclampsia at first and second trimester: Correlation with the week of onset and the severity. Prenat Diagn 2008; 28:704-709.
38. Dekker G, Sibai B. Primary, secondary, and tertiary prevention of pre-eclampsia. Lancet 2001; 357:209-215. (Pubitemid 32108113)